Photo of Martin T King,  MD, PhD

Martin T King, MD, PhD

Brigham And Women's Hospital

Brigham And Women's Hospital

Martin T King, MD, PhD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Radiation Oncology, Harvard Medical School
  • Physician, Radiation Oncology, Dana-Farber Cancer Institute
  • Physician, Radiaton Oncology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Martin King is an expert in prostate and gynecologic brachytherapy. He is interested in identifying therapeutic strategies that can improve quality of life for men receiving radiation therapy for prostate cancer. He is the principal investigator of a multi-center randomized controlled trial, which evaluates whether a novel second-generation anti-androgen Darolutamide can be utilized in place of traditional androgen deprivation therapy for preserving erectile function while not sacrificing the potential for long-term disease control. Patients will be stratified by a genomic classifier as well as extreme radiation dose-escalation (e.g. brachytherapy boost). Other areas of research interest involve radiation for radiorecurrent prostate cancer, as well as therapeutic de-escalation of combination radiation treatments for unfavorable risk prostate cancer. Dr. King is part of the Brachytherapy Clinical Operations Leadership Team, and is an assistant professor of radiation oncology at Harvard Medical School. He is heavily involved in teaching medical students and residents the radiotherapeutic management of prostate and gynecologic cancers with external beam radiation therapy and brachytherapy.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Alimena S, Davis M, Pelletier A, Terry K, King M, Feldman S. Regional Variation in Access to Oncologic Care and Racial Disparities Among Cervical Cancer Patients. Am J Clin Oncol 2022; 45:415-421. PubMed
  • Kaza E, Lee CY, King MT, Dyer MA, Cormack RA, Buzurovic I. First pointwise encoding time reduction with radial acquisition (PETRA) implementation for catheter detection in interstitial high-dose-rate (HDR) brachytherapy. Brachytherapy 2022. PubMed
  • Lee LJ, Alban GM, Cheng T, Buzurovic I, Pretz J, Singer L, King MT. Clinical outcomes and dosimetric predictors of toxicity for re-irradiation of vaginal recurrence of endometrial cancer. Brachytherapy 2022. PubMed
  • King MT, Yang DD, D'Amico AV, Buzurovic I, Harris TC, Guthier CV, Steele GS, Kathrins MN, Choudhury AD. Risk-adaptive paradigm for focal versus whole-gland salvage treatment for radio-recurrent prostate cancer. 2022; 12:998390. PubMed
  • Russo AL, Lee LJ, Wo JY, Niemierko A, Park D, Alban G, King M, Philp L, Growdon WB, Oliva E, Spriggs DR, Yeku OO. Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal Brachytherapy. Am J Clin Oncol 2022; 45:36-39. PubMed
  • King MT, Keyes M, Frank SJ, Crook JM, Butler WM, Rossi PJ, Cox BW, Showalter TN, Mourtada F, Potters L, Stock RG, Kollmeier MA, Zelefsky MJ, Davis BJ, Merrick GS, Orio PF. Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy 2021. PubMed
  • Leeman JE, Chen YH, Catalano P, Bredfeldt J, King M, Mouw KW, D'Amico AV, Orio P, Nguyen PL, Martin N. Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. Int J Radiat Oncol Biol Phys 2021. PubMed
  • Yerramilli D, Chen YH, Venkatachalam V, Alban GM, Buscariollo DL, Cheng T, King MT, Pretz JL, Russo AL, Lee LJ. Adjuvant Radiation Field Extent and Sites of Failure in Node Positive Endometrioid Endometrial Cancer. 2021. PubMed
  • King MT, Chen MH, Collette L, Neven A, Bolla M, D'Amico AV. Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Netw Open 2021; 4:e2111092. PubMed
  • Alban G, Cheng T, Adleman J, Buzurovic I, Pretz J, Singer L, King M, Lee L. Definitive radiotherapy for vaginal recurrence of early-stage endometrial cancer: survival outcomes and effect of mismatch repair status. Int J Gynecol Cancer 2021. PubMed
  • Buzurovic IM, O'Farrell DA, Harris TC, Friesen S, King MT, Cormack RA, Devlin PM. Selection criteria for high-dose-rate surface brachytherapy and electron beam therapy in cutaneous oncology. J Contemp Brachytherapy 2021; 13:195-204. PubMed
  • Alimena S, Pachigolla SL, Feldman S, Yang D, Orio PF, Lee L, King M. Race- and Age-Related Disparities in Cervical Cancer Mortality. J Natl Compr Canc Netw 2021. PubMed
  • Leung SOA, Feldman S, Kalyanaraman R, Shanmugam V, Worley MJ, Berkowitz RS, Horowitz NS, Feltmate CM, Muto MG, Lee LJ, King MT, Einarsson JI, Ajao MO, Elias KM. Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. Am J Reprod Immunol 2021. PubMed
  • Dee EC, Muralidhar V, King MT, Martin NE, D'Amico AV, Mouw KW, Orio PF, Nguyen PL, Leeman JE. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. Radiother Oncol 2021; 161:241-250. PubMed
  • Dee EC, Muralidhar V, Arega MA, Kishan AU, Spratt DE, Dess RT, King MT, Sha ST, Santos PMG, Butler SS, Sanford NN, Nguyen PL, Mahal BA. Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2020. PubMed
  • Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer Prostatic Dis 2020. PubMed
  • Yang DD, Muralidhar V, Mahal BA, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Martin NE, King MT, Mouw KW, Choueiri TK, Trinh QD, Nguyen PL, Orio PF. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urol Oncol 2020; 38:735.e9-735.e15. PubMed
  • Lamba N, Butler S, Mahal BA, Trinh QD, Rose B, King M, Orio P, Mouw KW, Martin N, Leeman JE, Feng FY, Nguyen PL, Muralidhar V. Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. Urology 2020. PubMed
  • Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw 2019; 17:941-948. PubMed
  • Muralidhar V, Mahal BA, Butler S, Lamba N, Yang DD, Leeman J, D'Amico AV, Nguyen PL, Trinh QD, Orio PF, King MT. Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer. J Urol 2019. PubMed
  • Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol 2019; 75:35-41. PubMed
  • Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med 2019; 380:2070-2072. PubMed
  • King MT, Nguyen PL, D'Amico AV, Orio PF. Reply to Partial gland therapy for prostate cancer. Cancer 2018. PubMed
  • King MT, Nguyen PL, Boldbaatar N, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV, Orio PF. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer 2018. PubMed
  • Yang DD, Muralidhar V, Mahal BA, Nguyen PL, Devlin PM, King MT, Orio PF. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys 2018; 100:53-58. PubMed
  • King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol 2017. PubMed
  • Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF, King MT. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2017; 99:904-911. PubMed
  • Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clin Genitourin Cancer 2017. PubMed
  • Singer L, McLaughlin PY, Alban G, Joyner M, King M, Lee L. Simulation-based graduate medical education in MR-guided brachytherapy for cervical cancer. Brachytherapy ; 19:725-731. PubMed
  • King MT, Nguyen PL, Boldbaatar N, Yang DD, Muralidhar V, Tempany CM, Cormack RA, Hurwitz MD, Suh WW, Pomerantz MM, D'Amico AV, Orio PF. Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy ; 18:198-203. PubMed
  • Brennan V, Spektor A, Sweeney C, Choudhury A, Rathkopf D, Pomerantz M, Hertan L, Nguyen P, Martin N, Balboni T, Huynh MA, King M. Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. Adv Radiat Oncol ; 7:100808. PubMed
  • King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D'Amico AV, Nguyen PL, Orio PF. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy ; 18:186-191. PubMed
  • Leeman JE, Cagney DN, Mak RH, Huynh MA, Tanguturi SK, Singer L, Catalano P, Martin NE, D'Amico AV, Mouw KW, Nguyen PL, King MT, Han Z, Williams C, Huynh E. Magnetic Resonance-Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort. Adv Radiat Oncol ; 7:100934. PubMed
  • King MT, Muralidhar V, Yang DD, Mouw KW, Martin NE, D'Amico AV, Nguyen PL, Orio PF. Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. Brachytherapy ; 20:1-9. PubMed
Hide